23andMe Holding Co. (ME)
- Previous Close
0.4604 - Open
0.4522 - Bid 0.4896 x 400
- Ask 0.4966 x 800
- Day's Range
0.4444 - 0.5036 - 52 Week Range
0.3500 - 2.2100 - Volume
4,975,519 - Avg. Volume
7,708,795 - Market Cap (intraday)
238.416M - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1100 - Earnings Date May 26, 2024 - May 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.23
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.
www.23andme.comRecent News: ME
Performance Overview: ME
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ME
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ME
Valuation Measures
Market Cap
238.42M
Enterprise Value
74.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.93
Price/Book (mrq)
0.63
Enterprise Value/Revenue
0.30
Enterprise Value/EBITDA
-0.25
Financial Highlights
Profitability and Income Statement
Profit Margin
-210.48%
Return on Assets (ttm)
-26.17%
Return on Equity (ttm)
-92.53%
Revenue (ttm)
247.99M
Net Income Avi to Common (ttm)
-521.97M
Diluted EPS (ttm)
-1.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
242.42M
Total Debt/Equity (mrq)
20.90%
Levered Free Cash Flow (ttm)
-116.44M
Research Analysis: ME
Company Insights: ME
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ME
Analyst Report: 23andMe Holding Co.
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Analyst Report: 23andMe Holding Co.
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Analyst Report: 23andMe Holding Co.
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Rating